1 A monitored release for triazolam was carried out in the United Kingdom during 1979. Three thousand and ten patients were involved‐ approximately one‐third were males and two‐thirds were females. 2 The majority of patients (71.3%) took 0.25 mg triazolam: 24.1% took 0.125 mg and only 4.4% took 0.5 mg and above. There were no differences between the sexes, but there were differences according to age. In the group over 60 y, 45.4% took 0.25 mg and 50.7% took 0.125 mg. 3 The majority of patients (84.7%) reported an adequate night's sleep, and the overall incidence of side effects in patients taking the drug was 12.2%.